Preoperative Hilar and Mediastinal Lymph Node Staging in Patients with Suspected or Diagnosed Lung Cancer: Accuracy of 18F-FDG-PET/CT:A Retrospective Cohort Study of 138 Patients

Damirov, Fuad; Büsing, Karen A.; Yavuz, Gökce; Hatz, Rudolf; Manapov, Farkhad; Michels, Julia; Hohenberger, Peter; Roessner, Eric Dominic

doi:10.3390/diagnostics13030403

Cited by 2 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For NSCLC patients, surgical resection is the primary treatment, significantly improving prognosis. However, those with lymph node or distant metastases require systematic lymph node dissection and additional metastatic treatment alongside lesion resection ( 32 , 33 ). These comprehensive approaches markedly enhance patient outcomes.…”

Section: Progress In the Application Of Pet-related Radiomics In Lung...mentioning

confidence: 99%

Current status and prospect of PET-related imaging radiomics in lung cancer

Tang,

Wu,

Chen

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Lung cancer is highly aggressive, which has a high mortality rate. Major types encompass lung adenocarcinoma, lung squamous cell carcinoma, lung adenosquamous carcinoma, small cell carcinoma, and large cell carcinoma. Lung adenocarcinoma and lung squamous cell carcinoma together account for more than 80% of cases. Diverse subtypes demand distinct treatment approaches. The application of precision medicine necessitates prompt and accurate evaluation of treatment effectiveness, contributing to the improvement of treatment strategies and outcomes. Medical imaging is crucial in the diagnosis and management of lung cancer, with techniques such as fluoroscopy, computed radiography (CR), digital radiography (DR), computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET)/CT, and PET/MRI being essential tools. The surge of radiomics in recent times offers fresh promise for cancer diagnosis and treatment. In particular, PET/CT and PET/MRI radiomics, extensively studied in lung cancer research, have made advancements in diagnosing the disease, evaluating metastasis, predicting molecular subtypes, and forecasting patient prognosis. While conventional imaging methods continue to play a primary role in diagnosis and assessment, PET/CT and PET/MRI radiomics simultaneously provide detailed morphological and functional information. This has significant clinical potential value, offering advantages for lung cancer diagnosis and treatment. Hence, this manuscript provides a review of the latest developments in PET-related radiomics for lung cancer.

show abstract

Section: Progress In the Application Of Pet-related Radiomics In Lung...mentioning

confidence: 99%

Current status and prospect of PET-related imaging radiomics in lung cancer

Tang,

Wu,

Chen

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Despite its accuracy (90%), sensitivity (78-85%), and specificity (87-92%) [6,7], integrated 18F-FDG-PET/CT has its limitations due to the frequent preoperative nodal upstaging in lung cancer patients [8,9]. Specifically, the occurrence of 18F-FDG-PET/CT false-positive LN metastasis was reported in up to 61% of NSCLC patients [9,10], due to concurrent infectious, inflammatory, or interstitial lung diseases [11,12].…”

Section: Introductionmentioning

confidence: 99%

Histology of the Primary Tumor Correlates with False Positivity of Integrated 18F-FDG-PET/CT Lymph Node Staging in Resectable Lung Cancer Patients

et al. 2023

Self Cite

View full text Add to dashboard Cite

This study aimed to evaluate the diagnostic accuracy and false positivity rate of lymph node (LN) staging assessed by integrated 18F-fluorodeoxyglucose positron emission computed tomography (18F-FDG-PET/CT) in patients with operable lung cancer to the tumor histology. In total, 129 consecutive patients with non-small-cell lung cancer (NSCLC) undergoing anatomical lung resections were included. Preoperative LN staging was evaluated in the relationship to the histology of the resected specimens (group 1: lung adenocarcinoma/LUAD; group 2: squamous cell carcinoma/SQCA). Statistical analysis was performed by the Mann–Whitney U-test, the chi2 test, and binary logistic regression analysis. To establish an easy-to-use algorithm for the identification of LN false positivity, a decision tree including clinically meaningful parameters was generated. In total, 77 (59.7%) and 52 (40.3%) patients were included in the LUAD and SQCA groups, respectively. SQCA histology, non-G1 tumors, and tumor SUVmax > 12.65 were identified as independent predictors of LN false positivity in the preoperative staging. The corresponding ORs and their 95% CIs were 3.35 [1.10–10.22], p = 0.0339; 4.60 [1.06–19.94], p = 0.0412; and 2.76 [1.01–7.55], and p = 0.0483. The preoperative identification of false-positive LNs is an important aspect of the treatment regimen for patients with operable lung cancer; thus, these preliminary findings should be further evaluated in larger patient cohorts.

show abstract

Preoperative Hilar and Mediastinal Lymph Node Staging in Patients with Suspected or Diagnosed Lung Cancer: Accuracy of 18F-FDG-PET/CT:A Retrospective Cohort Study of 138 Patients

Cited by 2 publications

References 25 publications

Current status and prospect of PET-related imaging radiomics in lung cancer

Current status and prospect of PET-related imaging radiomics in lung cancer

Histology of the Primary Tumor Correlates with False Positivity of Integrated 18F-FDG-PET/CT Lymph Node Staging in Resectable Lung Cancer Patients

Contact Info

Product

Resources

About